Massachusetts-based RNA startup Orbital Therapeutics announced that its lead RNA immunotherapy candidate, OTX-201, achieved full B cell depletion in blood, spleen, and lymph nodes — required for an effective immune system reset in autoimmune disease — in a non-human primate study.
OTX-201 comprises an optimized circular RNA encoding a CD19-targeted CAR delivered via targeted lipid nanoparticles (LNPs) with in vivo administration. This in vivo approach, in which the patient’s own body serves as the manufacturer of CAR-T cells, has the potential to offer a reduced treatment burden and improved accessibility compared to ex vivo CAR-T therapies, which require patient cell collection and complex manufacturing processes followed by intensive conditioning regimens prior to infusion.
Based on preclinical findings to date, Orbital — launched in 2023 as a spinout of Beam Therapeutics and currently helmed by former Spark Therapeutics CEO Ron Philip — is advancing OTX-201 through IND-enabling studies and plans to begin clinical development in the first half of 2026.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!